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Methods: We describe the clinical and neuroimaging characteristics of loss-of-function mutation
carriers initially presenting with frontotemporal lobar degeneration (FTLD) phenotypes.
Results: Two carriers initially presented semantic variant of FTLD (svFTLD); two other developed
nonfluent variant of FTLD (nfvFTLD) and corticobasal syndrome (CBS), associated with severe
anterior temporal and opercular atrophy. All secondarily developed ALS.
Discussion: This study enlarges the phenotypic spectrum of TBK1mutations, including svFTLD and
nfvFTLD/CBS, not reported so far. Aphasic presentations seem to be more evocative of TBK1 geno-
type than behavioral variant of FTLD, and TBK1 should be analyzed in patients with isolated FTLD at
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Frontotemporal lobar degeneration (FTLD) defined three
variants characterized by behavioral (behavioral variant of
FTLD [bvFTLD]) or language disorders (semantic variant
of FTLD [svFTLD] and agrammatic/nonfluent variant of
FTLD [nfvFTLD]) [1,2]. Amyotrophic lateral sclerosis
(ALS) and FTLD share common pathologic hallmarks and
genetic etiologies, the most frequent being C9orf72.
Recently, TBK1 loss-of-function mutations were identi-
fied as a rare genetic cause involved in 0.5%–4% of ALS
[3,4]. Associated phenotypes have not been deeply defined
so far. In this study, we describe in detail the clinical and
neuroimaging characteristics of four loss-of-function muta-
tion carriers initially presenting with FTLD phenotypes.2. Methods
2.1. Patients and families
We studied four unrelated probands from unrelated
French (F476, F484, and F826) and Portuguese (F500)
families carrying TBK1 loss-of-function mutations
(Fig. 1A, Table 1). The mutations were identified by ge-
netic screening of 302 unrelated FTLD patients (143 fa-
milial) including 182 probands with isolated FTLD (118
bvFTLD, 50 nfvFTLD, 2 svFTLD, and 12 progressive
supranuclear paralysis) and 120 that secondarily devel-
oped ALS (113 bvFTLD, 5 nfvFTLD, and 2 svFTLD
Supplementary Material). The main FTLD and ALS
gene have been previously excluded in all the probands.
The proband 003 and one relative 005 of family F484 car-
ried the p.Thr156ArgfsX6 mutation; the proband 003 of
family F500 carried a p.Tyr482X mutation, that was also de-
tected in four unaffected sibs aged 59–77 years; the probands
003 of family F826 and 003 of family F476 carried
p.Gln655X and p.Leu654LysfsX18 mutations, respectively.
This study was approved by the Ethics Committee of “AP-
HP de Paris.”2.2. Clinical and neuroimaging evaluations of patients
The phenotypes have been assessed by clinical evalua-
tions of patients, interview of caregivers, and in medical
records. Brain magnetic resonance imaging (MRI) and
single-photon emission computed tomography (SPECT)
were done in routine procedures. The diagnoses were based
on international criteria [1,2,5].3. Results
3.1. Description of FTLD phenotypes (Table 1)
Patient 003 of family F826 presented language disor-
ders with predominant semantic deficit at age 64.
Computed tomography scan revealed predominantly left,
temporal anterior atrophy. At age 65, the mini-mental
state examination (MMSE; 25/30), oral confrontation
naming (22/40), and Boston Naming Test (13/30) scores
were impaired, as well as semantic matching (35/40),
famous faces recognition (13/50), and visual recognition
memory scores (DMS48:42; Supplementary Table 1). He
secondarily developed apathy, immotivate laughing, klep-
tomania, and stereotypies. At age 66, MRI revealed severe
bi-temporal, predominantly left, atrophy (Fig. 1B1). He
developed ALS with limb deficit and swallowing disor-
ders, confirmed by electromyograms (EMG). He died at
age 69. A parent 001 died of dementia, at age 83.
Patient 003 of family F500 presented language disor-
ders with predominant semantic deficit, at age 68. MRI
and HMPAO-SPECT showed marked bilateral, predomi-
nant marked left, anterior temporal involvement
(Fig. 1B2) associated with mild frontal involvement.
The oral confrontation naming (12/80, 11 semantic para-
phasias), visual naming (9/18), and semantic matching
(5/10) scores were impaired (Supplementary Table 1). A
svFTLD was diagnosed. He secondarily presented apathy,
indifference, stereotypies, right akinetic-rigid Parkin-
sonism, and a dysexecutive syndrome (Supplementary
Table 1). At age 70, he developed spinal ALS (ALS-
FRS: 24/48) and died at age 71. One sib died of ALS at
age 50 (DNA was not available for this sib).
Proband 003 of family F484 developed language disor-
ders, severe orofacial apraxia, and reduced speech evoca-
tive of agrammatic nonfluent aphasia, at age 60. The oral
confrontation naming score (25/30) was impaired. Atten-
tion and memory were spared. MRI revealed bilateral
but predominantly left temporal atrophy (Fig. 1B3).
EMGs were normal. At age 63, he had marked apathy,
gestural and eyelid apraxia, and akinetic-rigid Parkin-
sonism. A nonfluent aphasic subtype of corticobasal syn-
drome (CBS) was diagnosed. Dysarthria and swallowing
disorders suggesting bulbar ALS developed later, without
muscular deficit. He died at age 65. One sib (005) pre-
sented spinal ALS without behavioral changes (Frontal
Behavioral Inventory score: 12/72) at age 76. No parents
had neurologic disorders.
Fig. 1. (A) Pedigrees of TBK1 families. The individuals are represented by diamonds for confidentiality. *Family members for whomDNA samples were avail-
able and carrying the mutation; black diamonds: FTLD or ALS patients; gray diamonds: unspecified dementia (UD); white diamonds: nonsymptomatic indi-
viduals. The FTLD and ALS phenotypes are indicated for the patients. Age at death (AAD) is indicated. The proband 003 of family F826 carried the
heterozygous c.1963C.T (p.Gln655X) mutation. In family F500, the proband 003 and four unaffected sibs (006, 007, 008, and 009), aged 59–77 years, carried
the heterozygous p.Tyr482X (c.1446T.G) mutation. In family F484, the FTLD proband, 003, and a sib with ALS (005) carried a p.Thr156ArgfsX6
(c.467_468delCA) mutation. The proband 003 of family F476 carried a p.Leu654LysfsX18 (c.1960-2A.G) mutation. (B) Neuroimaging of TBK1 patients.
(1) Patient F826-003. Axial FLAIR MRI sections, after 2 years of disease duration (at age 66), showing bilateral predominantly left anterior temporal atrophy.
(2) Patient F500-003. Axial FLAIR and T2-weighted MRI sections and axial HMPAO-SPECT, after 1 year of disease duration (age 69). Marked bilateral but
predominant left anterior temporal atrophy and hypoperfusion. The frontal cortex showed only mild involvement. (3). Patient F484-003. Axial T2 MRI sections
at age 61 (1 year of disease duration), showing predominant left temporal anterior atrophy; frontal cortex is relatively spared. (4). Patient F476-003. Axial ECD-
SPECT sections after 1 year of disease duration (at age 77) evidenced predominant left opercular and anterior temporal hypoperfusion (left). After 2 years of
disease duration (at age 78), SPECT (middle) and FLAIR MRI sections (right) showing bilateral predominantly left anterior, lateral, and middle temporal re-
gions, opercular, and bilateral frontal involvement. Abbreviations: FTLD, frontotemporal lobar degeneration; ALS, amyotrophic lateral sclerosis; MRI, mag-
netic resonance imaging; FLAIR, flair-attenuated inversion recovery; SPECT, single-photon emission computed tomography; DD, disease duration; L, left; R,
right.
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Table 1
Main clinical characteristics of probands with FTLD (F826-003, F500-003, F484-003, and F476-003) carrying TBK1 mutations
Families Patients Mutations
Age
at onset
FTLD
First
FTLD
symptom
FTLD
diagnosis
Late FTLD
symptoms
occurring
during
disease
progression
Other
symptoms
Age
at onset
ALS
MRI
(years of disease)
SPECT
(years of disease)
Age
at death
F826 003 (proband) c.1963C.T
(p.Gln655X)
64 Semantic
deficits
svFTLD Apathy, immotivate
laughing,
kleptomania,
and stereotypies
Spinal ALS 66 Predominant left
anterior temporal
atrophy (2)
NA 69
F500 003 (proband) c.1446T.G
(p.Tyr482X)
68 Semantic
deficits
svFTLD Apathy, indifference,
and stereotypies
Spinal ALS, Park 70 Marked bilateral,
predominantly
left anterior
temporal atrophy.
Mild frontal
atrophy (1)
Predominant left
anterior temporal
hypoperfusion (1)
71
F484 003 (proband) c.467_468delCA
(p.Thr156ArgfsX6)
60 Speech
apraxia
nfvFTLD/
CBS
Apathy Spinal ALS, Park 64 Predominant left
temporal
atrophy (1)
NA 65
005 (relative) c.467_468delCA
(p.Thr156ArgfsX6)
— — — — Spinal ALS 76 NA NA 81
F476 003 (proband) c.1960-2A.G
(p.Leu654LysfsX18)
76 Speech
apraxia
nfvFTLD Disinhibition Spinal ALS 78 Bilateral
predominantly left
anterior, lateral,
middle temporal
and opercular
atrophy. Bilateral
frontal atrophy (2)
Left opercular and
anterior temporal (1).
Predominant left
anterior, lateral and
middle temporal,
opercular, and
bilateral frontal
hypoperfusion (2)
80
Abbreviations: FTLD, frontotemporal lobar degeneration; ALS, amyotrophic lateral sclerosis; MRI, magnetic resonance imaging; SPECT, single-photon emission computed tomography; svFTLD, semantic
variant of FTLD; NA, not applicable; nfvFTLD, nonfluent variant of FTLD; Park: parkinsonism; CBS, corticobasal syndrome.
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speech production deficit at age 76, without orofacial
muscular deficit, fasciculation, or atrophy. Speech exam-
ination evidenced severe orofacial apraxia with major
difficulties in words articulation evocative of a speech
apraxia. 99mTc-ethylcysteinate dimer (99mTc-ECD)
SPECT evidenced predominant left opercular and ante-
rior temporal hypoperfusion (Fig. 1B4). The clinical
and neuroimaging features were consistent with
nfvFTLD. EMGs were normal. He later developed disin-
hibition, euphoria, perseverations, imitation behaviors,
and marked frontal syndrome (Frontal Assessment Bat-
tery [FAB]: 12/18; MMSE: 24/30). At age 78, he devel-
oped moderate limb weakness, enhanced reflexes, and
Babinski sign. MRI and 99mTc-ECD-SPECT showed
predominant left anterior, lateral, and middle temporal
regions, opercular and bilateral frontal involvement
(Fig. 1B4). The FAB score was 9/18. He died at age
80. The parent, 001, developed dementia and died at
age 65; one sib 007 died at age 35 of “poliomyelitis.”4. Discussion
So far, TBK1 loss-of-function mutations have been
mainly reported in rare patients with ALS, isolated or
secondarily associated with dementia [3,4], and in one
patient only with FTLD [6], whose clinical phenotype has
not been precisely described. In this study, we report the first
detailed description of clinical, cognitive, and neuroimaging
characteristics of four TBK1 probands who presented inau-
gural FTLD phenotypes. These cases now clearly demon-
strate the direct relation, not coincidental, between FTLD
presentations and TBK1 mutations.
Strikingly, none of these patients had typical bvFTLD at
onset. Two initially presented semantic dementia with
temporopolar atrophy, not reported so far; two other devel-
oped predominant orofacial and speech apraxia consistent
with nfvFTLD at onset. One of the latter secondarily devel-
oped Parkinsonism and limb apraxia consistent with criteria
of possible nfvFTLD/CBS [7]. This study, thus, shows that
the TBK1 phenotypes are larger than initially reported,
including semantic dementia, speech apraxia, and
nfvFTLD/CBS, and our series suggest that these phenotypes
could be more frequently associated with this genotype than
bvFTLD.
Interestingly, four of seven (57%) of our subset of patients
with svFTLD or nfvFTLD associated with ALS carried a
mutation. nfvFTLD and svFTLD are usually much more
rarely associated with ALS than bvFTLD [8,9], except in
TBK1 carriers as demonstrated in this study. This is
supported by the recent description of one patient carrying
both TBK1 and OPTN mutations who also initially
developed nfvFTLD [6]. This genotype seems, therefore,
rather distinct from C9orf72, where classic behavioral
variant is largely the predominant FTLD presentation
[10,11]. Neuroimaging characteristics were strikinglysimilar in all cases, showing predominant severe anterior
temporal and opercular atrophy at onset, with only mild or
moderate frontal involvement, and were well correlated
with these phenotypes.
Ages at onset were variable, from 50 to 76 years in our
families. A previous study indicated a high penetrance of
TBK1 mutations in ALS families [4]. Our study suggests
that penetrance after the age of 70 years is lower than previ-
ously estimated because three carriers of family F500 were
unaffected at age 70–77. If confirmed in larger cohorts,
this result will have important implications for genetic coun-
seling.
Finally, this study will have important impact for clinical
practice. It enlarges the phenotypic spectrum of the disease
and contributes to define neuroimaging characteristics asso-
ciated with this genotype. Both FTLD and ALS phenotypes
can be associated with TBK1 mutations, showing no clear
correlation between the phenotype and genotype. The inter-
familial and intrafamilial phenotypic variability character-
izing TBK1 carriers is not explained by the mutations, all
producing haploinsufficiency as a common effect.
Importantly, aphasic presentations could be more charac-
teristic of TBK1 mutations than the bvFTLD, although this
observation should be confirmed in larger series of patients
with sv/nfvFTLD with ALS. This study, thus, suggests that
TBK1 mutations should be also searched for in patients pre-
senting with isolated FTLD at onset, particularly in rare
aphasic cases who secondarily develop ALS.Acknowledgments
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1. Systematic review: TBK1 mutations are a rare novel
genetic cause of amyotrophic lateral sclerosis (ALS)
without or with dementia, but the full spectrum of
TBK1 phenotypes has not been completely defined
so far. We describe in detail the clinical characteris-
tics of TBK1 mutation carriers presenting with iso-
lated frontotemporal lobar degeneration (FTLD) at
onset.
2. Interpretation: All patients presented aphasic and se-
mantic disorders at onset, a presentation not reported
so far. This study thus contributes to enlarge the
phenotypic spectrum of TBK1 mutations, and sug-
gest that this presentation could be evocative of this
genotype, more than the behavioral variant of FTLD.
3. Future directions: These findings will have important
impact for clinical practice, showing that the TBK1
gene should be analyzed not only in ALS but also
in patients who initially present with isolated
FTLD at onset, particularly in rare aphasic cases
that secondarily develop ALS.References
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